10Elms LLP’s Novartis NVS Stock Holding History

10Elms LLP’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$107K	Hold	700	–	–	0.07%	124
2025 Q4	$96.5K	Hold	700	–	–	0.09%	129
2025 Q3	$89.8K	Hold	700	–	–	0.08%	140
2025 Q2	$84.7K	Hold	700	–	–	0.08%	146
2025 Q1	$78K	Buy	+700	New	+$74.5K	0.08%	154
2024 Q4	–	Hold	0	–	–	–	168

Other funds holding NVS

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

10Elms LLP's NVS Position: Q1 2026 in Review

10Elms LLP held its Novartis (NVS) position steady in Q1 2026 at 700 shares worth $107K. The position accounts for 0.07% of the portfolio, ranked #124.

10Elms LLP first reported a position in NVS in Q1 2025 and has held it in 5 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

10Elms LLP held 700 shares of Novartis worth $107K as of Q1 2026.
10Elms LLP left its Novartis share count unchanged in Q1 2026.
Novartis made up 0.07% of 10Elms LLP's portfolio in Q1 2026, its #124 holding.
10Elms LLP first reported a position in Novartis in Q1 2025 and has held it in 5 quarters since.
1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on 10Elms LLP's 13F filing for Q1 2026, filed 15 May 2026.